N72482AT4 Filings — Qiagen N.v.

FilingSpy

N72482AT4 Filings — Qiagen N.v. - FilingSpy

Last event

Aug 7

6-K

Events · 12 mo

8-K + 6-K

Earnings releases

Item 2.02 · 12 mo

Leadership changes

Item 5.02 · 12 mo

Aug 7, 2026Shareholder vote6-K

QIAGEN N.V. held its 2026 Annual General Meeting on June 24, 2026.

Shareholders voted on the adoption of 2025 annual accounts, dividend, discharge of directors, and reappointments.

Show details

The Annual General Meeting took place on June 24, 2026, in Venlo, the Netherlands.
Proposals included reappointing Thierry Bernard and Roland Sackers as Managing Directors and eight Supervisory Directors.
Shareholders voted on amending the Managing Board Remuneration Policy and authorizing share issuance and buybacks.
A proposal allowed a capital repayment of up to $200 million via a synthetic share repurchase, subject to approval.

Primary filing Press release EX-99.2 EX-99.3 EX-99.4 EX-99.5 EX-99.6 EX-99.7 EX-99.8

Aug 7, 2026Earnings6-K

QIAGEN Q2 2026 net sales flat at $535M, adjusted EPS $0.62, beats outlook; reaffirms FY2026 guidance

Q2 2026 net sales were $535 million, unchanged year-over-year on a reported and CER basis, exceeding the outlook for an about 2% CER decline.

Show details

Adjusted diluted EPS was $0.62 (reported and CER), above the outlook of at least $0.60 CER; reported diluted EPS was $0.50.
Growth pillars (Sample technologies, QIAcuity, QDI) grew about 5% CER; QuantiFERON sales rose 1% CER despite lower U.S. immigration testing demand.
Adjusted operating income margin was 29.4% in Q2 2026, down from 29.9% in Q2 2025; H1 2026 operating cash flow was $301 million.
Full-year 2026 outlook reaffirmed: net sales growth of about 1-2% CER and adjusted diluted EPS of at least $2.43 CER.

Primary filing Press release

Aug 7, 2026Earnings6-K

QIAGEN reports Q2 2026 net sales of $535.0M, net income of $103.4M

Net sales for Q2 2026 were $535.0 million, up from $533.5 million in Q2 2025.

Show details

Net income for Q2 2026 was $103.4 million, up from $96.3 million in Q2 2025.
Diluted EPS for Q2 2026 was $0.50, up from $0.44 in Q2 2025.
Cash and cash equivalents were $768.5 million as of June 30, 2026, down from $839.0 million at year-end 2025.
The company declared a cash dividend of $0.35 per share in Q2 2026, up from $0.25 per share in Q2 2025.

Primary filing Press release

May 8, 2026Earnings6-K

QIAGEN Q1 2026 net sales $492M, adjusted EPS $0.54, in line with outlook

Q1 2026 net sales rose 2% reported to $492M, but declined 1% at constant exchange rates (CER) vs. prior year.

Show details

Adjusted diluted EPS was $0.54 (also $0.54 CER), in line with the outlook for at least $0.54 CER.
QuantiFERON sales fell 5% CER due to significantly lower immigration testing demand in the U.S. and Middle East.
Full-year 2026 outlook updated: net sales growth of about 1-2% CER (previously at least 5%) and adjusted diluted EPS of at least $2.43 CER (previously at least $2.50).
Free cash flow was $54M in Q1 2026, down from $96M in Q1 2025, reflecting higher investments and restructuring payments.

Primary filing Press release

May 8, 2026Earnings6-K

QIAGEN N.V. reports Q1 2026 net sales of $492.3 million, net income of $68.0 million

Diluted EPS was $0.33, compared to $0.41 in Q1 2025.

Show details

Net sales for Q1 2026 were $492.3 million, up from $483.5 million in Q1 2025.
Net income was $68.0 million, down from $90.8 million in the prior-year quarter.
Cash and cash equivalents totaled $646.3 million as of March 31, 2026, down from $839.0 million at year-end 2025.
The company completed a capital repayment of $496.7 million during the quarter.

Primary filing Press release

May 1, 2026Earnings6-K

QIAGEN reports preliminary Q1 2026 net sales of $492M, updates FY2026 outlook

Preliminary Q1 2026 net sales were $492 million, up 2% reported and down 1% at constant exchange rates (CER) versus prior year.

Show details

Adjusted diluted EPS for Q1 2026 expected to be $0.54 on a reported basis and $0.54 CER, in line with outlook.
QuantiFERON sales declined 5% CER due to significantly lower immigration testing demand in the U.S. and Middle East.
Full-year 2026 net sales growth outlook reduced to about 1-2% CER (previously at least 5% CER); adjusted EPS outlook lowered to at least $2.43 CER (previously at least $2.50 CER).
Q2 2026 net sales expected to decline about 2% CER from $534 million in Q2 2025; adjusted EPS expected at least $0.60 CER.

Primary filing Press release

Feb 6, 2026Earnings6-K

QIAGEN Q4 2025 net sales $540M, FY 2025 $2.09B, 2026 outlook at least 5% CER growth

Adjusted diluted EPS for Q4 2025 was $0.62 CER, above the outlook of about $0.60; FY 2025 adjusted diluted EPS was $2.40 CER, ahead of the outlook of about $2.38.

Show details

Q4 2025 net sales rose 4% to $540 million, with 1% CER growth, exceeding the outlook for steady results.
Full-year 2025 net sales grew 6% to $2.09 billion, with 5% CER growth, at the high end of the outlook.
For 2026, QIAGEN expects net sales growth of at least 5% CER and adjusted diluted EPS of at least $2.50 CER.
Growth pillars delivered $1.49 billion CER in 2025 sales, up 8% CER, and are expected to contribute about $1.64 billion CER in 2026.

Primary filing Press release

Dec 22, 2025Buyback6-K

QIAGEN to complete ~$500M synthetic share repurchase on January 7, 2026

QIAGEN announced details for completing a synthetic share repurchase of up to approximately $500 million, with the last trading day of pre-split shares on January 7, 2026.

Show details

The plan combines a direct capital repayment of $2.29 per pre-consolidation share with a reverse stock split consolidating every 20 shares into 19, reducing issued shares by about 10.9 million.
The capital return is expected to reduce issued shares by approximately 5% and enhance earnings per share.
QIAGEN will have returned at least $1 billion to shareholders by end-2028, well ahead of schedule, and is considering additional return measures.
The repayment will be made from existing cash reserves, with consolidated shares trading under current tickers (QIA, QGEN) starting January 8, 2026.

Primary filing Press release